Topics

Nektar quickly drops opioid drug after FDA panel rejection

06:40 EST 15 Jan 2020 | BioPharmaDive

After a decade of research, the biotech said it will withdraw its application for oxycodegol and make no further investment in the drug.

Original Article: Nektar quickly drops opioid drug after FDA panel rejection

NEXT ARTICLE

More From BioPortfolio on "Nektar quickly drops opioid drug after FDA panel rejection"

Quick Search

Relevant Topics

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...